Sanofi (SNY) · Pharmaceuticals
Sanofi Q2 2026 earnings: summary, key numbers & outlook
Results filed 30 Jul 2026 · Quarter ended 30 Jun 2026
Press release ↗Investor relations ↗
Summaries and transcripts are machine-generated and can contain errors.
In brief
Sanofi bought Dynavax for its two-dose adult hepatitis B vaccine while dropping amlitelimab and itepekimab, and a new CEO began reprioritizing the pipeline around Dupixent and newer launches.
Sanofi closed the Dynavax acquisition on February 10, 2026, adding HEPLISAV-B, a two-dose adult hepatitis B vaccine, and a shingles candidate. Dupixent gained approvals in allergic fungal rhinosinusitis and pediatric chronic spontaneous urticaria, while Ayvakit and ALTUVIIIO also drove growth. Tzield, Cenrifki and subcutaneous Sarclisa won new approvals, but several late-stage programs failed or were stopped.
Belén Garijo became CEO on May 1, 2026, after Paul Hudson was removed, and management has begun pipeline prioritization. The company is adding in-licensed assets such as rovadicitinib and KT501 while ending programs that did not clear the bar. The tension is that Dupixent remains the top seller and its primary US compound patent expires in March 2031, so replacements must mature in time.
No call transcript for this quarter, so this summary also draws on: DCAT Value Chain Insights ↗.
Key numbers
- Net sales (first half 2026) · GAAP
- €22,106 million
- Net income attributable to equity holders (first half 2026) · GAAP
- €1,957 million
- Diluted EPS (first half 2026, €) · GAAP
- 1.62
- Business EPS (first half 2026) · non-GAAP
- €3.97
- Gross profit as % of net sales (first half 2026) · GAAP
- 78.7%
- Operating income (first half 2026) · GAAP
- €3,168 million
- Operating income as % of net sales (first half 2026) · GAAP
- 14.3%
- Net cash from continuing operating activities (first half 2026, € million) · GAAP
- 4.6B
11.1% higher than in the first half of 2025
versus €5,812 million in the first half of 2025
versus 4.72 in the first half of 2025
up 17.1%
versus 77.7% in the first half of 2025
versus €3,759 million in the first half of 2025
versus 18.9% in the first half of 2025
versus 3,367 in the first half of 2025
| Segment or metric | Value | Change |
|---|---|---|
| Net sales growth at constant exchange rates (first half 2026) | 15.7% | |
| Dynavax net sales contribution since acquisition | €144 million | |
| Net debt at June 30, 2026 (€ million) | 15.5B | versus 11,008 at December 31, 2025 |
Where each number comes from
- Net sales (first half 2026): “Net sales for the first half of 2026 amounted to €22,106 million, 11.1% higher than in the first half of 2025.”
- Net income attributable to equity holders (first half 2026): “Net income attributable to equity holders of Sanofi amounted to €1,957 million in the first half of 2026, versus €5,812 million in the first half of 2025.”
- Diluted EPS (first half 2026, €): “Diluted earnings per share from discontinued operations (€) | 0.02 | 2.33 Diluted earnings per share (in euros) | 1.62 | 4.72”
- Business EPS (first half 2026): “Business EPS was €3.97 for the first half of 2026 (up 17.1%) compared with the 2025 first-half figure of €3.39”
- Gross profit as % of net sales (first half 2026): “Other revenues | 1,438 | 6.5% | 1,452 | 7.3% Cost of sales | (6,155) | -27.8% | (5,881) | -29.6% Gross profit | 17,389 | 78.7% | 15,460 | 77.7%”
- Operating income (first half 2026): “In the first half of 2026, Operating income amounted to €3,168 million, versus €3,759 million in the first half of 2025”
- Operating income as % of net sales (first half 2026): “Fair value remeasurement of contingent consideration | (37) | (61) Restructuring costs and similar items | (563) | (430) Other gains and losses, and litigation | (95) | (57) Operating income | 3,168 | 14.3% | 3,759 | 18.9%”
- Net cash from continuing operating activities (first half 2026, € million): “Net cash provided by/(used in) continuing operating activities | 4,643 | 3,367 Net cash provided by/(used in) operating activities of the discontinued Opella business | — | 188”
- Net sales growth at constant exchange rates (first half 2026): “At constant exchange rates (CER)(1), net sales rose by 15.7%, driven mainly by strong performances for Dupixent, Ayvakit and ALTUVIIIO.”
- Dynavax net sales contribution since acquisition: “Dynavax's contributions to Biopharma segment net sales and business operating income (for a definition refer to Note B.21. “Segment Information”) since the acquisition date amount to €144 million and €89 million, respectively.”
- Net debt at June 30, 2026 (€ million): “Net debt (a) | 15,513 | 11,008 (a)Net debt does not include lease liabilities, which amounted to €1,904 million as of June 30, 2026”
Copied from the press release ↗ and other documents in the SEC filing ↗. A figure is published only if its sentence is in those documents.
Key takeaways
Dynavax deal adds adult vaccine and shingles candidate
Sanofi completed the acquisition on February 10, 2026, bringing HEPLISAV-B, marketed in the US with a two-dose, one-month schedule versus three doses over six months, plus shingles candidate Z-1018 in phase 1/2. It deepens Sanofi's adult immunization offering.
Dupixent keeps widening its label
The FDA approved Dupixent for allergic fungal rhinosinusitis, and the FDA and European Commission approved it for children aged two to 11 with chronic spontaneous urticaria. Japan approved it for bullous pemphigoid, but Sanofi withdrew its EU application there and lichen simplex chronicus phase 3 studies missed their endpoints.
Amlitelimab and itepekimab dropped from the pipeline
Sanofi will not file amlitelimab in atopic dermatitis because the evidence does not show a meaningful improvement over standard of care, and itepekimab was discontinued in COPD and chronic rhinosinusitis. Riliprubart's MOBILIZE phase 3 in CIDP was also stopped for likely insufficient efficacy.
New CEO Belén Garijo starts pipeline prioritization
The Board removed Paul Hudson as CEO in February, Olivier Charmeil served as interim, and Belén Garijo took over on May 1, 2026. An Executive Committee reshuffle takes effect September 1, 2026, with a dedicated head of Research & Development.
Licensing deals refill immunology and oncology pipeline
Sanofi licensed rovadicitinib, a JAK/ROCK inhibitor already approved in China for myelofibrosis, with an upfront payment of $135 million. It also licensed Kali Therapeutics' tri-specific T-cell engager KT501 for autoimmune disease.
Questions
What did Sanofi acquire this quarter and why?
Sanofi completed the Dynavax acquisition on February 10, 2026, gaining the marketed adult hepatitis B vaccine HEPLISAV-B and the shingles candidate Z-1018. It strengthens Sanofi's adult immunization presence.
Which programs did Sanofi stop?
Sanofi will not file amlitelimab in atopic dermatitis, discontinued itepekimab in COPD and chronic rhinosinusitis, and halted the riliprubart MOBILIZE study in CIDP. Venglustat also missed its primary endpoint in two Fabry disease phase 3 studies.
Who leads Sanofi now?
Belén Garijo became CEO on May 1, 2026, succeeding Paul Hudson, whom the Board relieved in February. Olivier Charmeil was interim CEO in between.
What is the main long-term risk to Dupixent?
Dupixent is Sanofi's top-selling product, and its primary US compound patent expires in March 2031. Pipeline setbacks make replacing it harder.
What new products or approvals moved forward?
Cenrifki won EU approval for non-relapsing secondary progressive MS, Tzield was approved for younger children and for recently diagnosed stage 3 type 1 diabetes, and subcutaneous Sarclisa was approved via an on-body injector. Venglustat has FDA priority review for type 3 Gaucher disease with a decision date of November 25, 2026.
Documents
SEC filing